<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623426</url>
  </required_header>
  <id_info>
    <org_study_id>119247</org_study_id>
    <secondary_id>U10EY024527</secondary_id>
    <nct_id>NCT02623426</nct_id>
  </id_info>
  <brief_title>Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial</brief_title>
  <acronym>MERIT</acronym>
  <official_title>Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHSPH Center for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>JHSPH Center for Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will
      compare the relative efficacy and safety of intravitreal methotrexate, intravitreal
      ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular
      edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a
      parallel design (1:1:1), randomized comparative trial with an anniversary close-out at the 6
      month clinic visit. The primary outcome is percent change in central subfield thickness from
      the baseline OCT measurement to the 12 week visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Macular edema (ME) is the most common structural complication and cause of visual impairment
      and legal blindness in uveitis patients. Traditional approaches to the treatment of uveitic
      ME have included the use of regional corticosteroid therapy, delivered periocularly,
      including posterior sub-Tenon's and orbital floor injections, or via the intravitreal route.
      While corticosteroid injections may reduce ME and improve vision, the effect is often
      variable with a limited duration. Persistent macular edema is a common occurrence and often
      requires repeated intravitreal injections of corticosteroids, which expose eyes to a
      significant risk of increased intraocular pressure ocular and cataract development. The often
      refractory nature of uveitic ME and its impact on visual function underscores the need to
      identify effective alternative medical therapeutic options. Recent pilot studies have shown
      intravitreal methotrexate (MTX) and intravitreal ranibizumab (Lucentis®, Genentech Inc., San
      Francisco, CA) to be promising treatments for uveitic ME, and intravitreal dexamethasone
      implant (Ozurdex®, Allergan, Irvine, CA) has recently been approved by the U.S. FDA for
      uveitic ME in patients with non-infectious uveitis. In addition to being effective,
      intravitreal MTX and ranibizumab potentially may have less ocular side effects than
      corticosteroids, particularly less IOP elevation. However, the relative efficacy of these
      treatments is unknown. The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory
      Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal
      methotrexate, ranibizumab, and dexamethasone implant. MERIT is a parallel design (1:1:1),
      randomized comparative effectiveness trial with an anniversary close-out at the 6 month
      clinic visit. The primary outcome is percent change in central subfield thickness from the
      baseline OCT measurement to the 12 week visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in central subfield thickness from the baseline OCT measurement</measure>
    <time_frame>At 12-week visit</time_frame>
    <description>The primary outcome is the percent change in central subfield thickness from the baseline OCT measurement at the 12-week visit. The assessment of OCT outcomes will be performed by masked readers. The 12-week visit was chosen as the time to assess the primary outcome because the ranibizumab treatment arm specifies injections at baseline, 4 weeks and 8 weeks in all participants, and because the peak benefit for the dexamethasone pellet appears to be at the 8 to 12 weeks.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Uveitis</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Dexamethasone intravitreal implant 0.7mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible eye(s) treated at study visit M01 (week 0).
Retreatment required at study visit M03 (8 weeks) if re-treatment criteria met.
Retreatment permitted at later time points if retreatment criteria met.
Re-treatment criteria:
Central subfield thickness greater than 1.1X upper limit of normal (330 μm for Zeiss and Topcon SD OCT and 352 μm for Heidelberg OCT) and/or cystoid space(s) within 1 mm central subfield.
IOP of &lt;25 mm Hg (treatment with ≤3 IOP-lowering agents permitted)
Minimum time between treatments: minimum target is 8 weeks after last injection but re-injection permitted as early as 51 days after last injection;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal methotrexate 400 µg in 0.1 mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible eye(s) treated at study visit M01 (week 0).
Retreatment required at M02 (4 weeks) and M03 (8 weeks) if retreatment criteria met.
Retreatment permitted at later time points if retreatment criteria met.
Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal ranibizumab 0.5 mg per 0.05 mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible eye(s) treated at study visits M01 (week 0), M02 (4 weeks), and M03 (8 weeks).
Retreatment permitted at M04 (12 weeks) and at later time points if retreatment criteria met.
Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.
Re-treatment permitted at later time points if re-treatment criteria met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone intravitreal implant 0.7 mg</intervention_name>
    <description>Standard preparation as described for intravitreal injections.</description>
    <arm_group_label>Dexamethasone intravitreal implant 0.7mg</arm_group_label>
    <other_name>Ozurdex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Methotrexate 400 µg</intervention_name>
    <description>Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.</description>
    <arm_group_label>Intravitreal methotrexate 400 µg in 0.1 mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Ranibizumab 0.5 mg</intervention_name>
    <description>Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.</description>
    <arm_group_label>Intravitreal ranibizumab 0.5 mg per 0.05 mL</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Patient level inclusion criterion

          1. 18 years of age or older;

             Eye level inclusion criteria - at least one eye must meet all of the following
             conditions

          2. Inactive or minimally active non-infectious anterior, intermediate, posterior or
             panuveitis, as defined by SUN132 criteria as ≤ 0.5+ anterior chamber cells, ≤ 0.5+
             vitreous haze grade and no active retinal/choroidal lesions for a minimum of 4 weeks;

          3. Macular edema (ME) defined as the presence of macular thickness greater than the
             normal range for the OCT machine being used (see cut points below), regardless of the
             presence of cysts, following an intravitreal corticosteroid injection (≥ 4 weeks
             following intravitreal triamcinolone injection or ≥ 12 weeks following intravitreal
             dexamethasone implant injection);

             Greater than 300 μm for Zeiss Cirrus Greater than 320 μm for Heidelberg Spectralis
             Greater than 300 μm for Topcon 3DOCT

          4. Baseline fluorescein angiogram that, as assessed by the study ophthalmologist, is
             gradable for degree of leakage in the central subfield;

          5. Best corrected visual acuity (BCVA) 5/200 or better;

          6. Baseline intraocular pressure &gt; 5 mm Hg and ≤ 21 mm Hg (current use of ≤3 intraocular
             pressure-lowering medications and/or prior glaucoma surgery are acceptable (Note:
             combination medications, e.g., Combigan, are counted as two IOP-lowering medications);

          7. Media clarity and pupillary dilation sufficient to allow OCT testing and assessment of
             the fundus.

        Exclusion criteria:

        Patient level exclusion criteria

          1. History of infectious uveitis in either eye;

          2. History of infectious scleritis of any type in either eye (Note: History of
             noninfectious scleritis that has been active in past 12 months is an eye-level
             exclusion -see #13 below);

          3. History of keratitis (with the exception of keratitis due to dry eye) in either eye;

          4. History of central serous retinopathy in either eye;

          5. Active infectious conjunctivitis in either eye;

          6. Oral prednisone dose &gt; 10 mg per day (or of an alternative corticosteroid at a dose
             higher than that equipotent to prednisone 10 mg per day) OR oral prednisone dose ≤ 10
             mg per day at baseline that has not been stable for at least 4 weeks (note: if patient
             is off of oral prednisone at baseline (M01 study visit) dose stability requirement for
             past 4 weeks does not apply);

          7. Systemic immunosuppressive drug therapy that has not been stable for at least 4 weeks
             (note: use of systemic methotrexate is acceptable as long as regimen has been stable
             for at least 4 weeks);

          8. Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline;

          9. Known allergy or hypersensitivity to any component of the study drugs;

         10. For women of childbearing potential: pregnancy, breastfeeding, or a positive pregnancy
             test; unwilling to practice an adequate birth control method (abstinence, combination
             barrier and spermicide, or hormonal) for duration of trial;

             Eye level exclusion criteria - at least one eye that meets all inclusion criteria
             cannot have any of the following conditions

         11. History of infectious endophthalmitis;

         12. History of severe glaucoma as defined by optic nerve damage (cup/disc ratio of ≥ 0.9
             or any notching of optic nerve to the rim);

         13. History of active noninfectious scleritis in past 12 months (Note: History of
             noninfectious scleritis is acceptable if the last episode of active scleritis resolved
             at least 12 months prior to enrollment);

         14. Presence of an epiretinal membrane noted clinically or by OCT that per the judgment of
             study ophthalmologist may be significant enough to limit improvement of ME (i.e.,
             causing substantial wrinkling of the retinal surface);

         15. Torn or ruptured posterior lens capsule

         16. Presence of silicone oil;

         17. Ozurdex administered in past 12 weeks;

         18. Anti-VEGF agent, intravitreal methotrexate, or intravitreal/periocular corticosteroid
             administered in past 4 weeks;

         19. Fluocinolone acetonide implant (Retisert) placed in past 3 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas A Jabs, MD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine, Mount Sinai, New York, NY</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet T Holbrook, PhD, MPH</last_name>
    <phone>443-287-5791</phone>
    <email>jholbro1@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth A Sugar, PhD</last_name>
    <email>esugar2@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jules Stein Eye Institute, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Garcia, BS</last_name>
      <phone>310-794-5604</phone>
      <email>garcia@jsei.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Holland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya Rao, MPH</last_name>
      <phone>415-476-6687</phone>
      <email>maya.rao@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Nisha Acharya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Huerta</last_name>
      <phone>305-326-6348</phone>
      <email>c.huerta1@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Janet Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alcides Fernandes, MD</last_name>
      <phone>404-778-2421</phone>
      <email>afilho@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Yeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Seddon, BS</last_name>
      <phone>312-695-0252</phone>
      <email>nreinhol@nm.org</email>
    </contact>
    <investigator>
      <last_name>Anjum Koreishi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Edwards, PhD, MPH</last_name>
      <phone>312-563-4031</phone>
      <email>carla_edwards@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Pauline T Merrill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacy Flanagan, BA</last_name>
      <phone>319-467-5184</phone>
      <email>lacy-flanagan@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>B</last_name>
    </contact_backup>
    <investigator>
      <last_name>James Folk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Bottorff, BS COA CCRC</last_name>
      <phone>502-852-5251</phone>
      <email>mlbott03@exchange.louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Harpal S Sandhu, MD FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kemi Adeyemo</last_name>
      <phone>443-287-4393</phone>
      <email>oadeyem2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Thorne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Caccaviello</last_name>
      <phone>617-573-5558</phone>
      <email>John_Caccaviello@MEEI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>George Papaliodis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Berry</last_name>
      <phone>617-314-2703</phone>
      <email>jberry@eyeboston.com</email>
    </contact>
    <investigator>
      <last_name>Lana M Rifkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kellogg Eye Center, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Campbell</last_name>
      <phone>734-936-0138</phone>
      <email>pamtitus@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Susan G Elner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MAYO Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Sultze</last_name>
      <phone>507-284-5833</phone>
      <email>sultze.jane@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Wendy Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Eye Center, Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LaToya Greene</last_name>
      <email>latoya.greene@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Glenn J Jaffe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scheie Eye Institute, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Karlik</last_name>
      <phone>215-662-8094</phone>
      <email>meghan.karlik@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>John H Kempen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MidAtlanitc Retina, Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Benfield</last_name>
      <phone>215-928-3092</phone>
      <email>hbenfield@midatlanticretina.com</email>
    </contact>
    <investigator>
      <last_name>James P Dunn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda J Dahlstrom, MA</last_name>
      <phone>412-383-9028</phone>
      <email>dahlstromrj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew W Eller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Ruark</last_name>
      <phone>615-936-1639</phone>
      <email>scott.ruark@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Sapna Gangaputra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsey Moore</last_name>
      <phone>713-524-3434</phone>
      <email>chelsey.moore@houstonretina.com</email>
    </contact>
    <investigator>
      <last_name>Rosa Y Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John A. Moran Eye Center, University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberley Wegner, BS, CRC</last_name>
      <phone>801-581-6265</phone>
      <email>kimberley.wegner@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Albert Vitale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victorian Eye and Ear Hospital</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thuy Chau</last_name>
      <phone>+61 3 9929 8087</phone>
      <email>thuy.chau@unimelb.edu.au</email>
    </contact>
    <investigator>
      <last_name>Lyndell Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3S5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Delpech</last_name>
      <phone>(514)934-1934</phone>
      <phone_ext>36814</phone_ext>
      <email>isabelle.delpech@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Jean Deschenes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 9EL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Shields</last_name>
      <phone>02072533411</phone>
      <phone_ext>4793</phone_ext>
      <email>Rebecca.Shields@moorfields.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Susan Lightman PhD, FRCOp FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jabs DA, Busingye J. Approach to the diagnosis of the uveitides. Am J Ophthalmol. 2013 Aug;156(2):228-36. doi: 10.1016/j.ajo.2013.03.027. Epub 2013 May 10.</citation>
    <PMID>23668682</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uveitic macular edema</keyword>
  <keyword>uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

